Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GGHS is a sulfated derivative of galactomannan, which is obtained from guar gum hydrolysis (GGH). It shares structural similarities with DAVANAT, a galectin-1 ligand with anticolorectal cancer activity, and possesses anticoagulant properties similar to heparin. In preclinical studies, GGHS has demonstrated antimelanoma effects by inhibiting melanoma cell invasion, increasing cell adhesion, and reducing colony size and proliferation. It binds to galectin-1 and galectin-3 and acts as an immunostimulatory agent by stimulating macrophage proinflammatory responses, including reactive oxygen species production and cytokine secretion. GGHS is being investigated for its potential as an immunostimulatory agent and as a melanoma adjuvant therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GGHS.